EANS-Adhoc: SYGNIS Pharma AG
SYGNIS announces acquisition of a loan from BASF SE

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.


Ad-hoc release

SYGNIS announces acquisition of a loan from BASF SE

Heidelberg,  29  June  2012  -  SYGNIS  Pharma   AG   (Frankfurt:   LIOK;   ISIN
DE000A1E9B74; Prime Standard) today announces  the  execution  of  an  agreement
effective 31 March 2012 with  BASF  SE  to  acquire  a  loan  amounting  to  EUR
8,000,000 for a purchase price of EUR 1.00 which equals the fair  value  of  the
loan. The loan was granted to SYGNIS Bioscience GmbH & Co.  KG,  a  wholly-owned
subsidiary of SYGNIS Pharma AG. The acquisition of  the  loan  is  part  of  the
necessary realignment of the Company. BASF is a shareholder  with  approximately
11 per cent in SYGNIS Pharma AG.

The acquisition of the loan at fair value will be accounted through  profit  and
loss in the consolidated financial statements ended 31 March 2012.

The loan granted to SYGNIS Bioscience GmbH & Co. KG in September  2006  was  due
for repayment on 30 June 2015. Interest was charged at the 3-month EURIBOR  plus
a customary mark-up.

For further information please contact:

|Peter Willinger                         |
|Co-CEO/CFO                              |
|Tel: +49 (0) 6221-454 836               |
|Email:           |

### Disclaimer

This publication is intended for information only  and  constitutes  neither  an
offer to sell nor an invitation to buy securities. Some statements  included  in
this press release, relating neither  to  proven  financial  results  nor  other
historical data, should be viewed as forward-looking, i.e.  not  definite.  Such
statements are mainly predictions of future results,  trends,  plans  or  goals.
These statements should not be considered to be  total  guarantees  since  given
their  very  nature  they  are  subject  to  known   and   unknown   risks   and
imponderability and can be affected by other factors as a consequence  of  which
the actual results, plans and goals of SYGNIS  Pharma  AG  may  deviate  greatly
from the established  conclusions  or  implied  predictions  contained  in  such
statements. SYGNIS does  not  undertake  to  publicly  update  or  revise  these
statements in the light of new information or future results or  for  any  other

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6

end of announcement                               euro adhoc 

issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             Stuttgart, regulated dealing/prime standard: Frankfurt 
language:   English

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: